论文部分内容阅读
目的探讨减量HAG方案在治疗高危骨髓增生异常综合征(MDS)中的疗效和安全性。方法 44例MDS患者,随机分为试验组和对照组,各22例。试验组采用减量HAG方案治疗,对照组采用单纯小剂量阿糖胞苷方案治疗,连续治疗2个疗程后,评价疗效及安全性。结果试验组治疗总有效率明显优于对照组,差异具有统计学意义(P<0.05);试验组有16例患者发生骨髓抑制,对照组有15例患者发生骨髓抑制,两组均不同程度出现非造血系统不良反应,不良反应发生率比较差异无统计学意义(P>0.05)。结论减量HAG方案治疗高危MDS疗效确切,安全性高,值得基层医院广泛开展和应用。
Objective To investigate the efficacy and safety of the reduced HAG regimen in the treatment of high risk myelodysplastic syndrome (MDS). Methods 44 patients with MDS were randomly divided into experimental group and control group, with 22 cases in each group. The experimental group was treated with reduced HAG regimen, while the control group was treated with simple low-dose cytarabine regimen. After two courses of continuous treatment, the curative effect and safety were evaluated. Results The total effective rate of the experimental group was significantly better than that of the control group (P <0.05). In the experimental group, 16 patients had myelosuppression and 15 patients had myelosuppression in the control group, both of which appeared in varying degrees Non-hematopoietic system adverse reactions, the incidence of adverse reactions was no significant difference (P> 0.05). Conclusions Decreased HAG regimen is effective and safe in treating high-risk MDS. It is worth widely used and implemented in primary hospitals.